Benjamin L. Palleiko - Aug 11, 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Benjamin L. Palleiko
Stock symbol: KALV
Transactions as of: Aug 11, 2025
Transactions value $: $0
Form type: 4
Date filed: 8/13/2025, 05:29 PM
Previous filing: Jul 10, 2025
Next filing: Aug 19, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER, Director	C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE	/s/ Benjamin L. Palleiko	2025-08-13	0001366244

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Restricted Stock Unit	Award	$0	+114K		$0.00	114K	Aug 11, 2025	Common Stock	114K		Direct	F1, F2
transaction	KALV	Employee Stock Option	Award	$0	+114K		$0.00	114K	Aug 11, 2025	Common Stock	114K	$12.51	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2	1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 11, 2025, subject to continued service through each vesting date.
F3	The option vests over a 4 year period: 1/48th on September 11, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.